Impact of Medication Use on [18F]MK6240 and [18F]Flortaucipir Uptake in Alzheimer's disease
Rayan Mroué, Pamela C.L. Ferreira, Guilherme Povala, Bruna Bellaver, Guilherme Bauer‐Negrini, Firoza Z Lussier, Livia Amaral, Marina Scop Madeiros, Emma Ruppert, Andreia Silva da Rocha, Matheus Scarpatto Rodrigues, Markley Silva Oliveira, Carolina Soares, Douglas Teixeira Leffa

TL;DR
This study examines how common medications might affect tau tracer uptake in Alzheimer's disease using PET imaging, but finds no significant associations after corrections.
Contribution
The study provides new evidence on the lack of significant medication effects on tau tracer uptake in Alzheimer's patients.
Findings
Anti-Diabetics were associated with lower SUVR in the NTC for both tracers in CI Aβ-positive individuals.
No significant associations remained after correction for multiple comparisons.
Medication use did not significantly influence MK or FTP uptake when accounting for covariates.
Abstract
Quantifying tau aggregates in the human brain can be achieved using Positron Emission Tomography (PET) techniques, which can potentially be affected by binding competition due to medication use. Patients with dementia often have high rates of comorbidities and polypharmacy. Therefore, this study aims to investigate the potential influence of multiple medications on the uptake of the tau tracers MK6240 (MK) and Flortaucipir (FTP). Five classes of medications were evaluated: Anti‐Hypertensives, Statins, Anti‐Diabetics, Psychoactive drugs, and NSAIDs (Table 1). We included 292 individuals [170 cognitively unimpaired (CU) Aβ‐negative and 122 cognitively impaired (CI) Aβ‐positive] from the HEAD study (Table 2). We compared MK and FTP SUVR in the Medial Temporal Lobe (MTL) and Neotemporal Cortex (NTC) in individuals on and off medications. The linear regressions that tested associations were…
Genes, proteins, chemicals, diseases, species, mutations and cell lines named across the full text — each resolved to its canonical identifier and authoritative record.
Click any figure to enlarge with its caption.
Figure 1
Figure 2
Figure 3Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsAlzheimer's disease research and treatments · Dementia and Cognitive Impairment Research · Schizophrenia research and treatment
